BioCentury
ARTICLE | Company News

Biogen, Novartis carve out space for their SMA therapies

October 22, 2019 11:49 PM UTC
Updated on Oct 23, 2019 at 2:24 AM UTC

Biogen and Novartis each posted consensus-beating quarters for their respective spinal muscular atrophy therapies, with ex-U.S. sales and a wider indication allowing Spinraza to stay in the game as gene therapy Zolgensma is poised to encroach on those markets.

Zolgensma onasemnogene abeparvovec-xioi from Novartis AG (NYSE:NVS; SIX:NOVN) brought in revenues of $160 million this quarter, beating expectations of $98 million...

BCIQ Company Profiles

Biogen Inc.

Novartis AG